T. Rowe Price Associates
PDLI

T. Rowe Price Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

T. Rowe Price Associates’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,355
Closed -$89K – 2781
2020
Q3 		$89K Buy
+28,355
New +$90.6K ﹤0.01% 2520

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
HW
Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

T. Rowe Price Associates's PDLI Position: Q4 2020 in Review

T. Rowe Price Associates sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 28,355 shares — an estimated $89K sold.

T. Rowe Price Associates first reported a position in PDLI in Q3 2020 and held it in 1 quarter. The position peaked at $89K in Q3 2020. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • T. Rowe Price Associates reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 28,355 PDL BioPharma, Inc. shares in Q4 2020, an estimated $89K.
  • T. Rowe Price Associates first reported a position in PDL BioPharma, Inc. in Q3 2020 and held it in 1 quarter.
  • T. Rowe Price Associates's PDL BioPharma, Inc. position peaked at $89K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.